Same Indication

Montelukast vs Rituximab

Montelukast vs Rituximab: Overview

This comparison examines the pharmacological differences between Montelukast and Rituximab.

Mechanism of Action

Montelukast: Selective leukotriene D4 receptor antagonist.

Rituximab: Chimeric anti-CD20 IgG1 monoclonal antibody inducing B-cell depletion via CDC, ADCC, and apoptosis.

Pharmacokinetics

Half-life: Montelukast — 2.7-5.5 hours; Rituximab — 22 days.

Chemical Properties

Molecular Formula: Montelukast — C35H36ClNO3S.

Molecular Weight: Montelukast — 586.1800 g/mol.

Type: Montelukast — Small molecule; Rituximab — Antibody.